60 citations
,
May 2015 in “Archives of dermatological research” This review discusses the role of peroxisome proliferator-activated receptors and their agonists in dermatology but reports no new clinical results.
38 citations
,
January 2017 in “PPAR Research” This review discusses the role of PPAR-γ in the pathogenesis of primary cicatricial alopecia, including its involvement in lichen planopilaris and treatment trials using PPAR-agonists, and reports no new clinical results.
1 citations
,
January 2025 in “American Journal of Translational Research” This study found that PPARα agonists provided protective effects in mouse models of alopecia areata by promoting early reversal of the condition and inhibiting T effector cell function, indicating potential therapeutic value for this inflammatory condition.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.
46 citations
,
November 2004 in “Lipids” This study suggests PPAR isotypes play distinct roles in skin, influencing epidermal barrier formation, sebocyte differentiation, and lipid production, with potential implications for treating skin disorders.